Scaffolding proteins mediating membrane-initiated extra-nuclear actions of estrogen receptor

Steroids

Volumn 76, Issue 9, 2011, Pages 877-884

  Boonyaratanakornkit, Viroj ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

AKT; eNOS; Estrogen receptor; MAPK; Membrane signaling; Signaling complex assembly

Indexed keywords

ADAPTOR PROTEIN; CALVASCULIN; CAVEOLIN; CRK ASSOCIATED SUBSTRATE PROTEIN; ESTROGEN RECEPTOR; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE 2; GLUTAMIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; MODULATOR OF NON GENOMIC ACTION OF ESTROGEN RECEPTOR; NCK PROTEIN; PROLINE; PROTEIN 14 3 3; PROTEIN KINASE B; PROTEIN P130; PROTEIN SHC; PROTEIN TYROSINE PHOSPHATASE 1B; SCAFFOLD PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

CELL DIFFERENTIATION; CELL MEMBRANE; CELL PROLIFERATION; CYTOPLASM; DNA SYNTHESIS; ENZYME ACTIVATION; GENETIC TRANSCRIPTION; HOMEOSTASIS; HUMAN; PALMITOYLATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN MODIFICATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BREAST NEOPLASMS; CAVEOLINS; ENDOTHELIAL CELLS; HISTONE DEACETYLASES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTEIN TRANSPORT; RECEPTORS, ESTROGEN; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 79959887451     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2011.02.017     Document Type: Review

References (107)

1. Tsai M, O'Malley B. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994;63:451-86. (Pubitemid 24218640)
2. Levin ER. Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol 2005;19:1951-9. (Pubitemid 41124194)
3. Boonyaratanakornkit V, Edwards DP. Receptor mechanisms mediating nongenomic actions of sex steroids. Semin Reprod Med 2007;25:139-53. (Pubitemid 46676901)
4. Mangelsdorf D, Tummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell 1995;83:835-9.
5. Beato M, Klug J. Steroid hormone receptors: an update. Hum Reprod Update 2000;6:225-36. (Pubitemid 30348891)
6. Pietras RJ, Szego CM. Specific binding sites of estrogen at the outer surface of isolated endometrial cells. Nature 1977;265:69-72. (Pubitemid 8004314)
7. Levin ER. Cellular functions of plasma membrane estrogen receptors. Steroids 2002;67:471-5. (Pubitemid 34311762)
8. Pappas TC, Gametchu B, Watson CS. Membrane estrogen receptor identified by multiple labeling impeded-ligand binding. FASEB J 1995;9:404-10.
9. Pedram A, Razandi M, Levin ER. Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol 2006;20:1996-2009. (Pubitemid 44286700)
10. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999;20:321-44. (Pubitemid 30649811)
11. Kuiper GGJM, Enmark E, Pelto HM, Nilsson S, Gustafsson Js-A. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996;93:5925-30. (Pubitemid 26190778)
12. Cowley SM, Parker MG. A comparison of transcriptional activition by ERα and ERβ. J Steroid Biochem Mol Biol 1999;69:165-75.
13. Hall JM, McDonnell DP. The estrogen receptor-β isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999;140:5566-78. (Pubitemid 30645344)
14. McInerney EM, Weis KE, Sun J, Mosselman S, Katzenellenbogen BS. Transcriptional activation by the human estrogen receptor subtype β (ERβ) studies with ERβ and ERα receptor chimeras. Endocrinology 1998;139:4513-22. (Pubitemid 28487767)
15. Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R, Santen RJ. The role of Shc and insulin-like growth factor I receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc Natl Acad Sci U S A 2004;101:2076-81. (Pubitemid 38229017)
16. Song RX-D, McPherson RA, Adam L, et al. Linkage of rapid estrogen action to MAPK activation of ERα-Shc association and Shc pathway activation. Mol Endocrinol 2002;16:116-27. (Pubitemid 34044502)
17. Razandi M, Pedram A, Greene GL, Levin ER. Cell membrane and nuclear estrogen receptors drive from a single transcript: studies of ERα and ERβ expressed in CHO cells. Mol Endocrinol 1999;13:307-19. (Pubitemid 29068005)
18. Kousteni S, Bellido T, Plotkin LI, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen recptors: dissociation from transcriptional activity. Cell 2001;104:719-30. (Pubitemid 32241022)
19. Razandi M, Pedram A, Merchenthaler I, Greene GL, Levin ER. Plasma membrane estrogen receptors exist and functions as dimers. Mol Endocrinol 2004;18:2854-65. (Pubitemid 39577911)
20. Abraham IM, Todman MG, Korach KS, Herbison AE. Critical in vivo roles for classical estrogen receptors in rapid estrogen actions on intracellular signaling in mouse brain. Endocrinology 2004;145:3055-61. (Pubitemid 38829969)
21. Evinger AJI, Levin ER. Requirement for estrogen receptor α membrane localization and function. Steroids 2005;70:361-3. (Pubitemid 40616033)
22. Razandi M, Oh P, Pedram A, Schnitzer J, Levin ER. ERs associates with and regulate the production of caveolin: implications for signaling and cellular actions. Mol Endocrinol 2002;16:100-15. (Pubitemid 34044501)
23. Razandi M, Alton G, Pedram A, Ghonshani S, Webb P, Levin ER. Identification of structural determinant necessary for the localization and fuction of estrogen receptor α at the plasma membrane. Mol Cell Biol 2003;23:1633-46. (Pubitemid 36246045)
24. Li L, Haynes MP, Bender JR. Plasma membrane localization and function of the estrogen receptor α variant (ER46) in human endothelial cells. Proc Natl Acad Sci U S A 2003;100:4807-12. (Pubitemid 36457810)
25. Marquez DC. Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells. Oncogene 2001;2001:5420-30. (Pubitemid 32889478)
26. Figtree GA, McDonald D, Watkins H, Channon KM. Truncated estrogen receptor variant (ER46) in human endothelial cells. Circulation 2003;107:120-6.
27. Li L, Hisamoto K, Kim KH, et al. Variant of estrogen receptor-c-Src molecular interdependence and c-Src structural requirements for endothelial NO synthase activation. Proc Natl Acad Sci U S A 2007;104:16468-73. (Pubitemid 350211042)
28. Metivier R, Penot G, Carmouche RP, et al. Transcriptional complexes engaged by apo-estrogen receptor-alpha isoforms have divergent outcomes. EMBO J 2004;23:3653-66. (Pubitemid 39336287)
29. Metivier R, Stark A, Flouriot G, et al. A dynamic structural model for estrogen receptor-alpha activation by ligands, emphasizing the role of interactions between distant A and E domains. Mol Cell 2002;10:1019-32. (Pubitemid 35453823)
30. Pedram A, Razandi M, Sainson RC, Kim JK, Hughes CC, Levin ER. A conserved mechanism for steroid receptor translocation to the plasma membrane. J Biol Chem 2007;282:22278-88. (Pubitemid 47267344)
31. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF. Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem Biophys Res Commun 2005;336:1023-7. (Pubitemid 41383424)
32. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF. A variant of estrogen receptor-α, hER-α36: transduction of estrogen- and antiestrogendependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci U S A 2006;103:9063-8. (Pubitemid 43902533)
33. Lin SL, Yan LY, Zhang XT, et al. ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways. PLoS One 2010;5:e9013.
34. Shi L, Dong B, Li Z, et al. Expression of ER-α36, a novel variant of estrogen receptor α, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol 2009;27:3423-9.
35. Glennery Jr JR, Soppet D. Sequence and expression of caveolin, a protein componet of caveolae plasma membrane domains phosphorylated on tyrosine in rouse sarcoma virus-tranformed fibroblast. Proc Natl Acad Sci U S A 1992;89:10517-21.
36. Rothenberg KG, Heuser JE, Donzell WC, Ying YS, Glennery Jr JR, Anderson RG. Caveolin, a protein component of caveolae membrane coats. Cell 1992;68:673-82.
37. Cohen AW, Hnasko R, Shubert W, Lisanti MP. Role of caveole and caveolins in health and disease. Physiol Rev 2004;84:1341-79. (Pubitemid 39287953)
38. Goetz JG, Lajoie P, Wiseman SM, Nabi IR. Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev 2008;27:715-35.
39. Scherer PE, Okamoto T, Chun M, Nishimoto I, Lodish HF, Lisanti MP. Identificaition, sequence and expression of caveolin-2 defines a caveolin gene family. Proc Natl Acad Sci U S A 1996;93:131-5. (Pubitemid 26041482)
40. Tang Z, Scherer PE, Okamato T, et al. Molecular cloning of caveolin-3, a novel member of caveolin gene family expressed predominantly in muscle. J Biol Chem 1996;271:2255-61. (Pubitemid 26047818)
41. Lisanti MP, Scherer PE, Vidugiriene J, et al. Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implication for human disease. J Cell Biol 1994;126:111-26. (Pubitemid 24214933)
42. Vogel U, Sandvig K, van Deurs B. Expression of caveolin-1 and polarized formation of invaginated caveolae in Caco-2 and MDCK II cells. J Cell Sci 1998;6:825-32. (Pubitemid 28163890)
43. Ikezu T, Ueda H, Trapp BD, et al. Affinity-purification and characterization of caveolin from the brain: differential expression of caveolin-1, -2 and -3 in brain endothelail and astroglial cell type. Brain Res 1998;804:177-92.
44. Ranzani B, Combs TP, Wong XB, et al. Caveolin-1-deficient mice are lean reistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J Biol Chem 2002;277:8635-47. (Pubitemid 34968330)
45. Galbiati F, Engelman JA, Volonte D, et al. Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distributionn of dystrophin-glycoprotein complex, and t-tubule abnormalities. J Biol Chem 2001;276:21425-33.
46. Ranzani B, Wang XB, Engelman JA, et al. Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae. Mol Cell Biol 2002;22:2329-44. (Pubitemid 34224637)
47. Razani B, Woodman SE, Lisanti MP. Caveolae: from cell biology to animal physiology. Pharmacol Rev 2002;54:431-67.
48. Kim HP, Lee JY, Leong JK, Bae SW, Lee HK, Jo I. Nongenomic stimulation of nitric oxide release by estrogen is mediated by estrogen receptor α localized in caveolae. Biochem Biophys Res Commun 1999;263:257-62. (Pubitemid 29443672)
49. Zschocke J, Manthey D, Bayatti N, van der Burg B, Goodenough S, Behl C. Estrogen receptor alpha-mediated silencing of caveolin gene expression in neuronal cells. J Biol Chem 2002;277:38772-80. (Pubitemid 35154740)
50. Williams TM, Medina F, Badano I, et al. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem 2004;279:51630-46. (Pubitemid 40017914)
51. Lee H, Park DS, Razani B, Russell RG, Lisanti MP. Caveolin mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia. Am J Pathol 2002;161:1357-69.
52. Li T, Sotgia F, Vuolo M, et al. Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor α-positive status. Am J Pathol 2006;168:1998-2013. (Pubitemid 43825319)
53. Zhang X, Shen P, Coleman M, et al. Caveolin-1 down-regulation activates estrogen receptor alpha expression and leads to 17beta-estradiol-stimulated mammary tumorigenesis. Anticancer Res 2005;25:369-75. (Pubitemid 40470132)
54. Fiucci G, Ravid D, Reich R, Liscovitch M. Caveolin-1 inhibits anchorage independent growth, anoikis and invasiveness in mMVF-7 human breast cancer cells. Oncogene 2002;21:2365-75. (Pubitemid 34413560)
55. Lee S, Reimer CL, Oh P, Campbell DB, Schnitzer JE. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 1998;16:1391-7. (Pubitemid 28151846)
56. Thompson TC, Timme TL, Li L, Goltsov A. Caveolin-1, a metastasis-related gene that promote cell survival in prostate cancer. Apoptosis 1999:233-7. (Pubitemid 29424486)
57. Tahir SA, Yang G, Ebara S, et al. Secreted caveolin-1 stimulates cell survival/ clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 2001;61:3882-5. (Pubitemid 32720945)
58. Liscovitch M, Burgermeister E, Jain N, Ravid D, Shatz M, Tencer L. Caveolin and cancer: a complex relationship. In: Mattson M, editor. Membrane microdomain signaling lipid rafts in biology and medicine. Totowa, NJ: Human Press; 2005. p. 161-90.
59. Castets F, Bartoli M, Barnier JV, et al. A novel calmodulin-binding protein, belonging to the WD-repeat family is localized in dendrites of a subset of CNS neurons. J Cell Biol 1996;134:1051-62. (Pubitemid 26278227)
60. Lu Q, Pallas DC, Surks HK, Baur WE, Mendelsohn ME, Karas RH. Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha. Proc Natl Acad Sci U S A 2004;101:17126-31. (Pubitemid 39627785)
61. Kumar P, Wu Q, Chambliss KL, et al. Direct interactions with Gαi and Gβγ mediate nongenomic signaling by estrogen receptor α. Mol Endocrinol 2007;21:1370-80. (Pubitemid 46984743)
62. Cabodi S, Moro L, Baj G, et al. p130Cas interacts with estrogen receptor α and modulates non-genomic estrogen signaling in breast cancer cells. J Cell Sci 2004;117:1603-11. (Pubitemid 38559834)
63. Sakai R, Iwamatsu A, Hirano N, et al. A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phophorylaion dependent manner. EMBO J 1994;13:3748-56.
64. Defilippi P, Stefano PD, Cabodi S. p130Cas: a versatile scaffold in signaling networks. Trends Cell Biol 2006;16:257-63. (Pubitemid 43728873)
65. Chodniewicz D, Klemke RL. Regulation of integrin-mediated cellular responses through assembly of a CAS/Crk scaffold. Biochem Biophys Acta 2004;1692:63-76. (Pubitemid 38891768)
66. O'Neil GM, Fashena SJ, Golemis EA. Integrin signaling a new Cas(t) of characters enters the stage. Trends Cell Biol 2000;10:111-9. (Pubitemid 30110694)
67. Brinkman A, van der Flier S, Kok EM, Dorssers LC. BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells. J Natl Cancer Inst 2000;2000:112-20. (Pubitemid 30089867)
68. van der Flier S, Chan CM, Brinkman A, et al. BCAR1/p130Cas expression in untreated and acquired tamoxifen-resistant human breast carcinomas. Int J Cancer 2000;89:465-8.
69. Cowell LN, Graham JD, Bouton AH, Clarke CL, O'Neil GM. Tamoxifen treatment promotes phosphorylation of the adhesion molecules p130Cas/BCAR1 FAK and Src, via an adhesion-dependent pathway. Oncogene 2006;25:7597-607. (Pubitemid 44924473)
70. Planas-Silva MD, Bruggeman RD, Grenko RT, Stanley Smith J. Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer. Biochem Biophys Res Commun 2006;341:73-81. (Pubitemid 43118368)
71. Sanchez AM, Flamini MI, Baldacci C, Goglia L, Genazzani AR, Simoncini T. Estrogen receptor-α promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP. Mol Endocrinol 2010;24:2114-25.
72. Li Y, Wang JP, Santen RJ, et al. Estrogen stimulation of cell migration involves multiple signaling pathway interactions. Endocrinology 2010;151:5146-56.
73. Ravichandran KS. Signaling via Shc family adapter proteins. Oncogene 2001;20:6322-30. (Pubitemid 32977841)
74. Sato K, Nagao T, Kakumoto M, et al. Adapter protein Shc is an isoform-specific direct activator of the tyrosine kinase c-Src. J Biol Chem 2002;277:29568-76. (Pubitemid 41079245)
75. Abramovich C, Chavez EA, Lansdorp PM, Humphries RK. Functional characterization of multiple domains involved in the subcellular localization of the hematopoietic Pbx interacting protein (HPIP). Oncogene 2002;21:6766-71. (Pubitemid 35221918)
76. Abramovich C, Shen WF, Pineault N, et al. Functional cloning and characterization of a novel nonhomeodomain protein that inhibits the binding of PBX1-HOX complexes to DNA. J Biol Chem 2000;275:26172-7.
77. Manavathi B, Acconcia F, Rayala SK, Kumar R. An inherent role of microtubule network in the action of nuclear receptor. Proc Natl Acad Sci U S A 2006;103:15981-6. (Pubitemid 44657578)
78. Wang X, Yang Z, Zhang H, et al. The estrogen receptor-interacting protein HPIP increases estrogen-responsive gene expression through activation of MAPK and AKT. Biochim Biophys Acta 2008;1783:1220-8.
79. Toh Y, Pencil SD, Nicloson GL. A novel candidate metastasis-associated gene MTA1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses. J Biol Chem 1994;269:22958-63.
80. Mazumdar A, Wang R-A, Mishra SK, et al. Transcriptional repression of estrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol 2001;3:30-7. (Pubitemid 32114829)
81. Gururaj AE, Singh RR, Rayala SK, et al. MTA1, a transcriptional activator of brast cancer amplified sequence 3. Proc Natl Acad Sci U S A 2006;25:6670-5.
82. Moon WS, Chang K, Tarnawski AS. Overexpression of metastatic tumor antigen 1 in hepatocellular carcinoma: relationship to vascular invasion and estrogen receptor-alpha. Hum Pathol 2004;35:424-9. (Pubitemid 38507078)
83. Kumar R, Wang R-A, Mazumdar A, et al. A naturally occurring MTA1 variant sequesters oestrogen receptor-α in the cytoplasm. Nature 2002;418:654-7.
84. Vadlamudi RK, Wang A, Mazumdar A, et al. Molecular cloning and characterization of PELP-1, a novel human coregulator of estrogen receptor α. J Biol Chem 2001;276:38272-9.
85. Barletta F, Wong C-W, McNally BS, Komm BS, Katzenellenbogen BS, Cheskis BJ. Characterization of the interactions of estrogen receptor and MNAR in the activation of c-Src. Mol Endocrinol 2004;18:1096-108. (Pubitemid 38591277)
86. Cheskis BJ, Greger J, Cooch N, et al. MNAR plays an important role in ERa activation of Src/MAPK and PI3K/Akt signaling pathways. Steroids 2008;73:901-5.
87. Nair SS, Mishra SK, Yang Z, Balasenthil S, Kumar R, Vadlamudi R. Potential role of a novel transcriptional coactivator PELP1 in histone H1 displacement in cancer cells. Cancer Res 2004;64:6416-23. (Pubitemid 39297895)
88. Vadlamudi RK, Balasenthil S, Broaddus RR, Gustafsson JA, Kumar R. Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors. J Clin Enocrinol Metab 2004;89:6130-8. (Pubitemid 39628425)
89. Rayala SK, Hollander P, Balasenthil S, et al. Hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) interacts with PELP1 and activates MAPK. J Biol Chem 2006;281:4395-403. (Pubitemid 43847871)
90. Rajhans R, Vadlamudi RK. Comprehensive analysis of recent biochemical and biologic findings regarding a newly discovered protein-PELP1/MNAR. Clin Exp Metastasis 2006;23:1-7. (Pubitemid 44576774)
91. Haas D, White SN, Lutz LB, Rasar M, Hammes SR. The modulator of nongenomic actions of estrogen receptor (MNAR) regulates transcription- independent androgen receptor-mediated signaling: evidence that MNAR participates in G protein-regulated meiosis in Xenopus laevis oocytes. Mol Endocrinol 2005;19:2035-46. (Pubitemid 41124199)
92. Chakravarty D, Nair SS, Santhamma B, et al. Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells. Cancer Res 2010;70:4092-101.
93. Vadlamudi RK, Manavathi B, Balasenthil S, et al. Functional implications of altered subcellular localization of PELP1 in breast cancer cells. Cancer Res 2005;65:7724-32. (Pubitemid 41297247)
94. Manavathi B, Nair SS, Wang RA, Kumar R, Vadlamudi RK. Proline-, glutamic acid-, and leucine-rich protein-1 is essential in growth factor regulation of signal transducers and activators of transcription 3 activation. Cancer Res 2005;65:5571-7. (Pubitemid 40911157)
95. Choi YB, Ko JK, Shin J. The transcriptional corepressor, PELP1, recruits HDAC2 and masks histones using two separate domains. J Biol Chem 2004;279:50930-41. (Pubitemid 40017832)
96. Balasenthil S, Vadlamudi RK. Functional interactions between the estrogen receptor coactivator PELP1/MNAR and retinoblastoma protein. J Biol Chem 2003;278:22119-27. (Pubitemid 36792622)
97. Unni E, Sun S, Nan B, et al. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res 2004;64:7156-68. (Pubitemid 39331031)
98. Habashy HO, Powe DG, Rakha EA, et al. The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype. Breast Cancer Res Treat 2010;120:603-12.
99. Kumar R, Zhang H, Holm C, Vadlamudi RK, Landberg G, Rayala SK. Extranuclear coactivator signaling confers insensitivity to tamoxifen. Clin Cancer Res 2009;15:4123-30.
100. Rajhans R, Nair HB, Nair SS, et al. Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells. Mol Endocrinol 2008;22:649-64. (Pubitemid 351397792)
101. Dimple C, Nair SS, Rajhans R, et al. Role of PELP1/MNAR signaling in ovarian tumorigenesis. Cancer Res 2008;68:4902-9.
102. Harrington WR, Sengupta S, Katzenellenbogen BS. Estrogen regulation of the glucuronidation enzyme UGT2B15 in estrogen receptor-positive breast cancer cells. Endocrinology 2006;147:3843-50. (Pubitemid 44079389)
103. Madak-Erdogan Z, Kieser KJ, Kim SH, Komm B, Katzenellenbogen JA, Katzenellenbogen BS. Nuclear and extranuclear pathway inputs in the regulation of global gene expression by estrogen receptors. Mol Endocrinol 2008;22:2116-27.
104. Rai D, Frolova A, Frasor J, Carpenter AE, Katzenellenbogen BS. Distinctive actions of membrane-targeted versus nuclear localized estrogen receptors in breast cancer cells. Mol Endocrinol 2005;19:1606-17. (Pubitemid 41002989)
105. Pedram A, Razandi M, Kim JK, et al. Developmental phenotype of a membrane only estrogen receptor alpha (MOER) mouse. J Biol Chem 2009;284:3488-95.
106. Fox EM, Bernaciak TM, Wen J, Weaver AM, Shupnik MA, Silva CM. Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells. Mol Endocrinol 2008;22:1781-96.
107. Pedram A, Razandi M, Aitkenhead M, Hughes CW, Levin ER. Integration of the non-genomic and genomic actions of estrogen. Membrane-initiated signaling by steroid to transcription and cell biology. J Biol Chem 2002;277:50768-75. (Pubitemid 36042240)